Controlled release of targeted chemotherapeutic drug dabrafenib for melanoma cancers monitored using surface-enhanced Raman scattering (SERS) spectroscopy
DOI:
https://doi.org/10.13171/mjc71/01803171500-hepelAbstract
The advanced skin cancer melanoma, which is primarily caused by the mutation of BRAF gene, has a high mortality rate and requires high doses of chemotherapeutic drugs. To mitigate the drug toxicity to healthy cells and other side effects, the development of alternative modes of treatment has been extensively sought after. Herein, we describe a new targeted drug delivery system with controlled release, based on nanoparticle nanocarriers functionalized with folate and transferrin ligands for recognition of the respective receptors overexpressed in cancer cell membrane. We have investigated the immobilization of a new drug dabrafenib onto the nanocarriers and its controlled release, aided with surface-enhanced Raman scattering (SERS) spectroscopy which affords ultra-sensitive in situ measurement ability owing to the high signal amplification, associated with strong plasmonic fields of the nanocarrier gold nanoparticle (AuNP) cores. The nanocarriers were equipped with Raman reporters: mercaptobenzoic acid (MBA) and para-aminothiophenol (PATP) forming a mixed thiolate monolayer shell on AuNPs. The dabrafenib was covalently attached to MBA via an amide bond which is pH sensitive and enables the drug release at lower pH encountered in cancer cells. This arrangement in the drug binding to the nanocarrier protects the dabrafenib amine group against deactivation until the drug release in the target tumor cells.References
- A.H. Shain and B.C. Bastian, Nat. Rev. Cancer, 2016, 16, 345-358.
- G.V. Long and e. al., J. Clin. Oncol., 2011, 29, 1239-1246.
- J. Shi, P.W. Kantoff, R. Wooster and O.C. Farokhzad, Nat. Rev. Cancer, 2017, 17, 20-37.
- M. Smith and M. Hepel, Mediterr. J. Chem., 2017, 6, 125-132.
- T. Santiago, R.S. DeVaux, K. Kurzatkowska, R. Espinal, J.I. Herschkowitz and M. Hepel, Int. J. Nanomed., 2017, 12, 7763-7776.
- K. Kurzatkowska, T. Santiago and M. Hepel, Biosens. Bioelectron., 2017, 91, 780-787.
- H. Ilkhani, T. Hughes, J. Li, C.J. Zhong and M. Hepel, Biosens. Bioelectron., 2016, 80, 257-264.
- A.M. Menzies, G.V. Long and R. Murali, Drug Des. Devel. Ther., 2012, 6, 391-405.
- S. Horn and et al., Science, 2013, 339, 959-961.
- F.W. Huang and et al., Science, 2013, 957-959.
- J.J. Grob, M.M. Amonkar, B. Karaszewska, J. Schachter, R. Dummer, A. Mackiewicz, D. Stroyakovskiy, K. Drucis, F. Grange, V. Chiarion-Sileni, P. Rutkowski, M. Lichinitser, et al., Lancet Oncol., 2015, 16, 1389-1398.
- L. Spain, M.J. M and J. Larkin, Expert Opin. Pharmacother., 2016, 17, 1031-1038.
- M. Schreuer, Y. Jansen, S. Planken, I. Chevolet, T. Seremet, V. Kruse and B. Neyns, Lancet Oncol., 2017, 18, 464-472.
- US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01052142?term.
- Y.T. Ko, C. Falcao and V.P. Torchilin, Mol. Pharm., 2009, 6, 971-977.
- Y.F. Zhang, J.C. Wang, D.Y. Bian, X. Zhang and Q. Zhang, Eur. J. Pharm. Biopharm., 2010, 74, 467-473.
- S. Sengupta and et al., Nature, 2005, 436, 568-572.
- J. Park and et al., Nat. Mater., 2012, 11, 895-905.
- A.A. Mouineer, A.F. Zaher, A.A. El-malah and E.A.e.-f. Sobh, Mediterr. J. Chem., 2017, 6, 165-179.
- J. Li, Z. Skeete, S. Shan, S. Yan, K. Kurzatkowska, W. Zhao, Q.M. Ngo, P. Holubovska, J. Luo, M. Hepel and C.J. Zhong, Anal. Chem., 2015, 87, 10698-10702.
- A. Hulikova, A.L. Harris, R.D. Vaughan-Jones and P. Swietach, J. Cell Physiol., 2013, 228, 743-752.
- Y. Kato, S. Ozawa, C. Miyamoto, Y. Maehata, A. Suzuki, T. Maeda and Y. Baba, Cancer Cell International, 2013, 13, 89.81-88.
- P. Swietach, R.D. Vaughan-Jones, A.L. Harris and A. Hulikova, Phil. Trans. R. Soc. B, 2014, 369, 20130099.
- J. Sudimack and R.J. Lee, Adv. Drug Deliv. Rev., 2000, 41, 147-162.
- R.C. Lynn, M. Poussin, A. Kalota, Y. Feng, P.S. Low, D.S. Dimitrov and D.J. Powell, Blood, 2015, 125, 3466-3476.
- D.R. Richardson, D.S. Kalinowski, S. Lau, P.J. Jansson and D.B. Lovejoy, Biochim. Biophys. Acta, 2009, 1790, 702-717.
- K. Ho, H. Li, Z. Qian and H. Sun, Pharm. Rev., 2002, 54, 561-587.
- J.J. Turek, C.P. Leamon and P.S. Low, J. Cell. Sci., 1993, 106, 423-430.
- Y. Lu and P.S. Low, Adv. Drug Deliv. Rev., 2002, 54, 675-693.
- M. Hepel and M. Stobiecka, J. Photochem. Photobiol. A, 2011, 225, 72-80.
- D.R. Richardson and P. Ponka, Biochim. Biophys. Acta, 1997, 1331, 1-40.
- E. Ryschich, G. Huszty, H.P. Knaebel, M. Hartel, M.W. Buchler and J. Schmidt, Eur. J. Cancer, 2004, 40, 1418-1422.
- M.R. Girotti and R. Marais, Cancer Discov., 2013, 3, 487-490.
- J.G. Samaritoni, A.T. Copes, D.K. Crews, C. Glos, A.L. Thompson, C. Wilson, M.J. O'Donnell and W.L. Scott, J. Org. Chem., 2014, 79, 3140-3151.
- M. Szostak, L. Yao and J. Aubé, J. Org. Chem., 2009, 74, 1869-1875.
- B.M. Brandsen, A.R. Hesser, M.A. Castner, M. Chandra and S.K. Silverman, J. Am. Chem. Soc., 2013, 135, 16014-16017.
- C. Zhou, J.L. Avins, P.C. Klauser, B.M. Brandsen, Y. Lee and S.K. Silverman, J. Am. Chem. Soc., 2016, 138, 2106-2109.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
